[8-K] Sidus Space, Inc. Reports Material Event

Rhea-AI Filing Summary

On 28 Jul 2025, TSSP Sub-Fund HoldCo, LLC and its managing member Alan Waxman jointly filed a Schedule 13G disclosing passive ownership in Caris Life Sciences, Inc. ("CAI") as of 30 Jun 2025.

• TSSP Sub-Fund HoldCo: 23,166,128 shares (8.3 % of the 277,932,779 outstanding).
• Alan Waxman: deemed beneficial owner of 24,385,399 shares (8.8 %) through control of HoldCo and related Sixth Street vehicles.
• Shares are distributed across five entities including Barnett Equity Holdings, Sixth Street Specialty Lending Inc. and related investment LLCs.

Both filers report zero sole and shared voting/dispositive power over the respective share counts; ownership is reported under Rule 13d-1(c) as a passive investment. No additional transactions, changes in control, or certifications were disclosed.

Positive

• Sixth Street-affiliated investors now hold an 8.8 % passive stake in CAI, adding a prominent institutional backer to the shareholder base.

Negative

• None.

Insights

Financial Analyst

TL;DR: Sixth Street affiliates reveal ~9 % passive stake in CAI; material for ownership mix but no control intent signaled.

The Schedule 13G indicates that Sixth Street–managed entities, via TSSP Sub-Fund HoldCo, accumulated 23.2 m CAI shares, while managing member Alan Waxman is deemed to control 24.4 m shares. At 8.3-8.8 % of outstanding stock, this represents a significant minority holding that must be reported but remains below activism thresholds. Because the filing is on Form 13G (not 13D), it signals no current intent to influence management, suggesting a passive, possibly credit-linked or crossover equity position typical of Sixth Street. From a valuation standpoint, new institutional support can tighten the float and may improve liquidity. However, absent any transactional detail or future plans, the disclosure is largely informational; fundamental outlook for CAI is unchanged.

false 0001879726 0001879726 2025-07-27 2025-07-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 27, 2025

SIDUS SPACE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41154		46-0628183
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

150 N. Sykes Creek Parkway, Suite 200 Merritt Island, FL		32953
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (321) 613-5620

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share		SIDU		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement

On July 27, 2025, Sidus Space, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with ThinkEquity LLC (“the “Placement Agent”), pursuant to which the Company agreed to issue and sell directly to investors, in a best efforts offering (the “Offering”) an aggregate of 7,143,000 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 (the “Common Stock”), at an offering price of $1.05 per Share.

The Shares were offered and sold by the Company pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-273430), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 26, 2023 and declared effective on August 14, 2023

The closing of the Offering is expected to occur on July 29, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds to the Company from the Offering are expected to be approximately $7.5 million, before deducting placement agent fees and expenses and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Offering for working capital and general corporate purposes.

Pursuant to the Placement Agency Agreement, the Company agreed to pay the Placement Agent a cash fee equal to 7.0% of the aggregate purchase price paid by the purchasers in the Offering. The Company also agreed to reimburse the Placement Agent for all reasonable and out-of-pocket expenses incurred in connection with the Placement Agent’s engagement, including reasonable fees and expenses of the Placement Agent’s legal counsel and due diligence analysis in an amount not to exceed $125,000. In addition, the Company agreed to issue to ThinkEquity or its designees warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 357,100 shares of the Company’s Common Stock. The Placement Agent Warrants are exercisable immediately upon issuance at an exercise price of $1.3125 per share and have a term of exercise equal to five years from the date of issuance.

The Placement Agency Agreement contains customary representations and warranties, agreements and obligations, conditions to closing and termination provisions. The foregoing descriptions of terms and conditions of the Placement Agency Agreement and the Placement Agent Warrants do not purport to be complete and are qualified in their entirety by the full text of the form of the Placement Agency Agreement and the form of Placement Agent Warrant, copies of which are attached hereto as Exhibits 1.1, and 4.1, respectively.

The legal opinion and consent of Sheppard, Mullin, Richter & Hampton LLP relating to the validity of the Securities issued in the Offering is filed herewith as Exhibit 5.1.

Item 8.01 Other Events.

On July 27, 2025, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
1.1		Placement Agency Agreement dated July 27, 2025
4.1		Form of Placement Agent Warrant
5.1		Opinion of Sheppard, Mullin, Richter & Hampton LLP
23.1		Consent of Sheppard, Mullin, Richter & Hampton LLP (included in Exhibit 5.1)
99.1		Press release of Sidus Space, Inc. dated July 27 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SIDUS SPACE, INC.
Dated: July 28, 2025
	By:	/s/ Carol Craig
	Name:	Carol Craig
	Title:	Chief Executive Officer

-3-

FAQ

Who filed the Schedule 13G for Caris Life Sciences (CAI)?

TSSP Sub-Fund HoldCo, LLC and its managing member Alan Waxman filed jointly.

How many CAI shares do the reporting persons own?

HoldCo reports 23,166,128 shares; Alan Waxman is deemed to own 24,385,399 shares.

What percentage of Caris Life Sciences’ outstanding stock is represented?

HoldCo owns 8.3 %; Alan Waxman controls 8.8 % of the 277,932,779 shares outstanding.

Is the stake considered passive or activist?

The filing is on Schedule 13G under Rule 13d-1(c), indicating a passive investment.

Under which CUSIP number was the filing made?

The filing references CUSIP 141252107.

When is the ownership date relevant to the filing?

Ownership is reported as of 30 June 2025.